Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$27.55
Change (%) Stock is Down 0.55 (1.96%)
Volume133,298
Data as of 11/17/17 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $27.55 with a 52 week high of $36.10 and a 52 week low of $16.30.
Recent NewsMore >>
DateTitle 
11/08/17REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights
Completed second cohort dosing in RGX-314 Phase I clinical trial for wet AMD Completed first cohort dosing in RGX-501 Phase I/II clinical trial for HoFH Interim trial updates to be included in the Company’s year-end 2017 corporate update scheduled to be released during the first week of January 2018 Initiated build-out of new 15,000 square foot, state-of-the-art Research and Development facility in Rockville, MD $191 million in cash, cash equivalents and marketable securities as of... 
Printer Friendly Version
11/01/17REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Nov. 01, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 8, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2017 and recent operational highlights. To access the live call by phone, dia... 
Printer Friendly Version
10/03/17REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following October investor conferences: Chardan Inaugural Gene Therapy Conference Date: Tuesday, October 10, 2017 Location: The Westin New York Grand Central Hotel Fireside chat: Tuesday, October 10... 
Printer Friendly Version
10/02/17REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics
Company Focused on Advancing Proprietary NAV Technology Platform and Deep Gene Therapy Treatment Pipeline ROCKVILLE, Md., Oct. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX) today announced that Dimension Therapeutics, Inc. (Nasdaq:DMTX) notified REGENXBIO that it has determined that it has received a “superior proposal” as defined in the merger agreement under which REGENXBIO would have acquired Dimension in an all-stock transaction for an implied value of approximately $3.41 per ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Presentations
DateTitle
11/08/17
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.